Latest Breaking News On - Phd cardiovascular research foundation - Page 1 : comparemela.com

Acute Decompensated Aortic Stenosis: Time for an Urgent TAVI Pathway?

A single-center study highlights the dire outcome for these ADAS patients, but also the perils of delaying care, even by days.

New yorkUnited statesCity ofUnited kingdomGuillaume bonnetMc kennaPatrickw serruysMichael mc kennaPhd cardiovascular research foundationMd barts healthUniversity hospital of bordeauxPhd university of galwayBarts healthDecompensated aortic stenosisCardiovascular research foundationUniversity hospital

More Early Insights Into Interatrial Shunts in HF, but Little to Focus the Field

First-in-human snapshots, pilot studies, roll-in cohorts, and post-hoc analyses showcase diverse technologies, but few certainties.

United statesNew yorkWilliam graySanjiv shahEdwards lifesciencesDaniel burkhoffSaibal karLos angelesMartinw bergmannPhd cardiovascular research foundationMd northwestern university feinberg school of medicineMd los robles health systemMd lankenau heart instituteHeart failure therapeuticsCardiovascular research foundationCorvia medical

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesJohn mullalyOrion pharmaDaniel burkhoffHeart failure society of americaCardiovascular research of the foundationLifesci advisorsJack skirball centerPhd cardiovascular research foundationColumbia universityCardiovascular research laboratoryExchange commissionCirculatory support researchJohns hopkins school of medicineOrion corporation of espoo finlandTenax therapeutics inc

Hints of Benefit With Levosimendan in Pulmonary Hypertension Due to HFpEF

April 15, 2021 For patients who have pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), treatment with levosimendan (Simdax; Tenax Therapeutics) can improve both pulmonary congestion and submaximal exercise capacity when compared with placebo, according to the results of a small study. While the phase II study missed its primary endpoint, which was a reduction in pulmonary capillary wedge pressure (PCWP) during exercise, levosimendan did reduce PCWPs across the rest, leg raise, and exercise stages. It also led to an improvement in 6-minute walk distance, investigators reported online April 7, 2021, in the Journal of the American College of Cardiology: Heart Failure.

New yorkUnited statesDaniel burkhoffJournal of the american college cardiologyWorld health organizationDrug administrationPhd cardiovascular research foundationCardiovascular research foundationTenax therapeuticsAmerican collegeHemodynamic evaluationபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்இதழ் ஆஃப் தி அமெரிக்கன் கல்லூரி இருதயவியல்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்ஃப்ட் இருதய ஆராய்ச்சி அடித்தளம்